Study to Assess Function and Satisfaction of Oral Ubrogepant in Adult Participants After Multiple Migraine Attacks In Canada

Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound. This study will evaluate function and satisfaction with oral ubrogepant in treating adult participants after multiple migraine attacks.

Ubrogepant is a drug approved for the acute treatment of migraine in adults. Approximately 167 participants will be enrolled in approximately 10-15 sites across Canada.

Participants will receive ubrogepant as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 12 weeks.

There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Migraine Brain Diseases Central Nervous System Diseases Headache Disorders Headache Disorders, Primary Migraine Disorders Nervous System Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Calgary Headache Assessment and Management Program /ID# 271475, Calgary, Alberta, Canada

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Participants able to give voluntary informed consent before starting any study-related assessments or procedures (to be obtained/documented as per local regulations).
Adults (≥18 years of age) at time of informed consent.
Participants with at least 1-year history of migraine with or without aura consistent with a diagnosis according to the ICHD-3 (2018).
Participants with history of experiencing at least 3 migraine attacks per month with moderate to severe symptoms
Participants prescribed ubrogepant by investigator for the acute treatment of migraine according to local product label, independent of and prior to study participation
Participants willing and able to comply with the requirements of the study.
Participants with access to an electronic device (mobile phone, tablet, laptop, etc.) with internet access.

Exclusion criteria

Participants previously exposed to a ubrogepant or rimegepant as routine therapy or through a clinical trial.
Participants with history of known contraindications to ubrogepant as per local labeling.
Participants Pregnant or planning to be pregnant or of childbearing potential not using contraception
Participants enrolled in any interventional studies that may include investigational compounds for migraine or non-AbbVie observational studies.
History or current evidence of any condition that might interfere with their ability to comply with the study requirements, in the opinion of the investigator.

Treatment and study plan

Primary outcomes

Percentage of Participants Achieving Functional Disability Scale (FDS) Score of =0, no disability, able to function normally 4 hours post-dose

Time frame: Up to approximately 12 weeks

Functional Disability Scale (FDS) is a Patient-Reported Outcome (PRO) assessing the ability of a participant to perform daily activities, rated on a 4-point scale (0=no disability, able to function normally; to 3=severely impaired, cannot do all or most things, bed rest may be necessary)

Sponsors and collaborators

Lead sponsor

AbbVie

Industry

Registry information

Official study title

Evaluation of Function And Satisfaction of UbrogepanT-treated Migraine Patients in Canada (FAST): Prospective, Observational, Real-world Study

Important dates

Study start: 2025
Primary completion: 2026
Study completion: 2026
First posted: Nov 18, 2024
Registry last updated: Jun 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed